Background: To compare the efficacy and tolerability of paliperidone extended-release (ER) with risperidone immediate-release using propensity score methodology. Methods: Six double-blind, randomized, ...
The FDA approved a new monthly paliperidone palmitate (Erzofri) extended-release injectable suspension for treating schizophrenia in adults, Luye Pharma announced. An atypical antipsychotic, ...
Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Paliperidone palmitate long-acting injectable therapy reduced schizophrenia symptom severity among ...
Please provide your email address to receive an email when new articles are posted on . Paliperidone palmitate appeared to benefit Black patients with recent-onset schizophrenia or schizophreniform ...
WASHINGTON, Oct. 2 (UPI) -- Johnson & Johnson received an approvable letter from the U.S. Food and Drug Administration for paliperidone for schizophrenia, but analysts were cautiously optimistic the ...
Learn everything you need to know about Paliperidone Palmitrate-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Hi everyone, I'm ...
Review the side-effects of Paliperidone Palmitrate as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In ...
In a 2022 decision involving Janssen and Pharmascience, the Federal Court found that the claims of Canadian Patent No. 2,655,335 (335 patent, relating to paliperidone palmitate (Janssen’s INVEGA ...
As previously reported, the Federal Court (FC) found that Teva would directly infringe but not induce infringement of certain claims of Canadian Patent No. 2,655,335 (335 patent) regarding its ...
This analysis used propensity score matching of subjects from randomized placebo-controlled schizophrenia studies to compare paliperidone ER 6–12 mg/day with risperidone 2–4 mg/day and risperidone 4–6 ...